Last reviewed · How we verify
Pantoprazole(Controloc)
Pantoprazole irreversibly inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
Pantoprazole irreversibly inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.
At a glance
| Generic name | Pantoprazole(Controloc) |
|---|---|
| Also known as | Controloc |
| Sponsor | Meridian Bioscience, Inc. |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Pantoprazole is a proton pump inhibitor (PPI) that binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing intragastric acidity. It is used to treat acid-related disorders by maintaining elevated gastric pH.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Zollinger-Ellison syndrome
- Prophylaxis of acid aspiration during anesthesia
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Flatulence
Key clinical trials
- Aspirin in Young Psychotic Patients (PHASE2, PHASE3)
- Vonoprazan Efficacy to Prevent Post Variceal Band Ligation Ulcer (PHASE3)
- Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter Pylori (PHASE3)
- 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors) (PHASE4)
- Pantoprazole in Cisplatin Nephrotoxicity (PHASE3)
- A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy (PHASE4)
- Clopidogrel Proton-Pump Inhibitors Study (PHASE4)
- Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pantoprazole(Controloc) CI brief — competitive landscape report
- Pantoprazole(Controloc) updates RSS · CI watch RSS
- Meridian Bioscience, Inc. portfolio CI